Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders

Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders

Abstract T cells are the current choice for many cell therapy applications. They are relatively easy to access, expand in culture, and genetically modify. Rapamycin‐conditioning ex vivo reprograms T cells, increasing their memory properties and capacity for survival, while reducing inflammatory pote...

Full description

Bibliographic Details
Main Authors: Murtaza S Nagree, Tania C Felizardo, Mary L Faber, Jitka Rybova, C Anthony Rupar, S Ronan Foley, Maria Fuller, Daniel H Fowler, Jeffrey A Medin
Format: Article
Language:English
Published: Springer Nature 2022-04-01
Series:EMBO Molecular Medicine
Subjects:
gene therapy
lentivirus
lysosomal storage disorders
T cells
Online Access:https://doi.org/10.15252/emmm.202114297

Internet

https://doi.org/10.15252/emmm.202114297

Similar Items